

Mechthild Krause

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8031877/publications.pdf>

Version: 2024-02-01

220
papers

10,562
citations

34493

54
h-index

45040

94
g-index

241
all docs

241
docs citations

241
times ranked

13421
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€”staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	2.6	26
2	Reduction of clinical safety margins in proton therapy enabled by the clinical implementation of dual-energy CT for direct stopping-power prediction. <i>Radiotherapy and Oncology</i> , 2022, 166, 71-78.	0.3	44
3	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.3	5
4	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 265-270.	0.4	1
5	European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. <i>Lancet Oncology</i> , The, 2022, 23, e21-e31.	5.1	117
6	Personalised radiation therapy taking both the tumour and patient into consideration. <i>Radiotherapy and Oncology</i> , 2022, 166, A1-A5.	0.3	7
7	Plasticity within Aldehyde Dehydrogenaseâ€”Positive Cells Determines Prostate Cancer Radiosensitivity. <i>Molecular Cancer Research</i> , 2022, 20, 794-809.	1.5	8
8	Cellular plasticity upon proton irradiation determines tumor cell radiosensitivity. <i>Cell Reports</i> , 2022, 38, 110422.	2.9	10
9	Tumour irradiation in mice with a laser-accelerated proton beam. <i>Nature Physics</i> , 2022, 18, 316-322.	6.5	62
10	Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1677.	1.7	7
11	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€” Hypothesis generation on a multicentre cohort of the DKTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.3	5
12	Radiomics-based tumor phenotype determination based on medical imaging and tumor microenvironment in a preclinical setting. <i>Radiotherapy and Oncology</i> , 2022, 169, 96-104.	0.3	11
13	Subjective memory impairment in glioma patients with curative radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
14	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
15	Importance of long-term follow up to address long-term effectiveness and toxicity of radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 170, 1-3.	0.3	1
16	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
17	Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia. <i>Acta OncolÃ³gica</i> , 2022, 61, 856-863.	0.8	4
18	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	1.7	2

#	ARTICLE	IF	CITATIONS
19	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	0.9	6
20	Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 63-73.	1.0	10
21	Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial. <i>Radiotherapy and Oncology</i> , 2021, 155, 285-292.	0.3	12
22	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
23	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 204-211.	0.3	5
24	The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. <i>Medical Sciences Forum</i> , 2021, 3, .	0.5	0
25	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
26	Radiation oncology in the new virtual and digital era. <i>Radiotherapy and Oncology</i> , 2021, 154, A1-A4.	0.3	8
27	Modelling of late side-effects following cranial proton beam therapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 15-23.	0.3	6
28	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 1865.	1.7	9
29	Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. <i>Radiotherapy and Oncology</i> , 2021, 158, 262-267.	0.3	4
30	Value of functional in-vivo endpoints in preclinical radiation research. <i>Radiotherapy and Oncology</i> , 2021, 158, 155-161.	0.3	3
31	Efficient Heat Shock Response Affects Hyperthermia-Induced Radiosensitization in a Tumor Spheroid Control Probability Assay. <i>Cancers</i> , 2021, 13, 3168.	1.7	3
32	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. <i>Oncogene</i> , 2021, 40, 4214-4228.	2.6	27
33	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiation Oncology</i> , 2021, 16, 141.	1.2	9
34	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. <i>Radiotherapy and Oncology</i> , 2021, 160, 69-77.	0.3	8
35	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e63-e74.	0.4	10
36	In reply to the Letter to the Editor by Chen and Lui regarding "Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial" by A Dietrich et al.. <i>Radiotherapy and Oncology</i> , 2021, 161, 261-262.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Reduced diffusion in white matter after radiotherapy with photons and protons. <i>Radiotherapy and Oncology</i> , 2021, 164, 66-72.	0.3	3
38	Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?. <i>Radiotherapy and Oncology</i> , 2021, 163, 177-184.	0.3	38
39	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1351-1360.	3.2	15
40	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5595.	1.7	4
41	Influence of the First Wave of the COVID-19 Pandemic on Cancer Care in a German Comprehensive Cancer Center. <i>Frontiers in Public Health</i> , 2021, 9, 750479.	1.3	9
42	Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. <i>International Journal of Cancer</i> , 2020, 147, 472-477.	2.3	36
43	Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 143, 44-50.	0.3	5
44	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
45	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 262-267.	0.3	12
46	A new prognostic hypoxia biomarker consisting of imaging and gene-based data. <i>EBioMedicine</i> , 2020, 58, 102901.	2.7	0
47	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19
48	Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3615-3625.	0.8	155
49	Radiotherapy and COVID-19 "everything under control or just the start of a long story?". <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 1065-1067.	1.0	2
50	UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells. <i>Oncolimmunology</i> , 2020, 9, 1743036.	2.1	25
51	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 189-196.	0.3	41
52	Applying Tissue Slice Culture in Cancer Research "Insights from Preclinical Proton Radiotherapy. <i>Cancers</i> , 2020, 12, 1589.	1.7	15
53	Specific requirements for translation of biological research into clinical radiation oncology. <i>Molecular Oncology</i> , 2020, 14, 1569-1576.	2.1	6
54	Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. <i>Radiotherapy and Oncology</i> , 2020, 143, 108-116.	0.3	24

#	ARTICLE	IF	CITATIONS
55	Refinement of the Hounsfield look-up table by retrospective application of patient-specific direct proton stopping-power prediction from dual-energy CT. <i>Medical Physics</i> , 2020, 47, 1796-1806.	1.6	15
56	Multi-modality bedding platform for combined imaging and irradiation of mice. <i>Biomedical Physics and Engineering Express</i> , 2020, 6, 037003.	0.6	7
57	Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1427-1436.	2.3	6
58	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	1.2	10
59	High-precision image-guided proton irradiation of mouse brain sub-volumes. <i>Radiotherapy and Oncology</i> , 2020, 146, 205-212.	0.3	16
60	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. <i>Cancers</i> , 2020, 12, 871.	1.7	9
61	Late Side Effects in Normal Mouse Brain Tissue After Proton Irradiation. <i>Frontiers in Oncology</i> , 2020, 10, 598360.	1.3	16
62	Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. <i>Frontiers in Oncology</i> , 2020, 10, 627379.	1.3	24
63	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. <i>Radiotherapy and Oncology</i> , 2019, 130, 164-171.	0.3	27
64	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 130, 10-17.	0.3	44
65	Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual γ H2AX. <i>Radiotherapy and Oncology</i> , 2019, 139, 94-100.	0.3	11
66	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3152-3163.	3.2	53
67	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 521-522.	12.5	3
68	Residual γ H2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. <i>Radiotherapy and Oncology</i> , 2019, 137, 24-31.	0.3	10
69	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 40-47.	0.9	32
70	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. <i>Acta Oncologica</i> , 2019, 58, 916-925.	0.8	11
71	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 43-50.	0.3	25
72	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 108-112.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 602.	2.2	8
74	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	3.2	67
75	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. <i>British Journal of Radiology</i> , 2019, 92, 20180539.	1.0	12
76	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019, 75, 548-551.	0.9	36
77	German Cancer Consortium (DKTK) – A national consortium for translational cancer research. <i>Molecular Oncology</i> , 2019, 13, 535-542.	2.1	22
78	Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. <i>Zeitschrift Fur Medizinische Physik</i> , 2019, 29, 216-228.	0.6	19
79	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , 2019, 130, 97-103.	0.3	14
80	Human gastric cancer modelling using organoids. <i>Gut</i> , 2019, 68, 207-217.	6.1	204
81	Predicting In Vitro Cancer Cell Survival Based on Measurable Cell Characteristics. <i>Radiation Research</i> , 2019, 191, 532.	0.7	6
82	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	5.1	108
83	Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score – report of the Radiation Oncology Group (<scp>ROG</scp>) of the German Cancer Consortium (<scp>DKTK</scp>). <i>Cancer Medicine</i> , 2018, 7, 1742-1749.	1.3	34
84	Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. <i>Radiotherapy and Oncology</i> , 2018, 128, 121-127.	0.3	48
85	Relative biological effectiveness in proton beam therapy – Current knowledge and future challenges. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 35-41.	0.9	96
86	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.3	37
87	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1393133.	2.1	17
88	Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy – Results of the randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , 2018, 126, 283-290.	0.3	7
89	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17
90	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	3.2	45

#	ARTICLE	IF	CITATIONS
91	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e161-e169.	2.2	67
92	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.3	24
93	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	2.3	50
94	Retrospective investigation of the prognostic value of the α 21 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy. <i>PLoS ONE</i> , 2018, 13, e0209479.	1.1	5
95	Heterogeneity of γ H2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2616.	1.8	5
96	“Radiobiology of Proton Therapy” Results of an international expert workshop. <i>Radiotherapy and Oncology</i> , 2018, 128, 56-67.	0.3	85
97	Research Facility for Radiobiological Studies at the University Proton Therapy Dresden. <i>International Journal of Particle Therapy</i> , 2018, 5, 172-182.	0.9	26
98	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 63-73.	6.6	247
99	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 437-444.	0.3	10
100	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017, 77, 2018-2028.	0.4	80
101	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
102	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. <i>Oncotarget</i> , 2017, 6, e1342909.	2.1	22
103	Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1813-1822.	3.3	12
104	The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 7-12.	0.9	8
105	Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. <i>Radiotherapy and Oncology</i> , 2017, 123, 282-287.	0.3	12
106	Clinical Implementation of Dual-energy CT for Proton Treatment Planning on Pseudo-monoenergetic CT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 427-434.	0.4	98
107	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
108	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , 2017, 124, 533-540.	0.3	123

#	ARTICLE	IF	CITATIONS
109	Proton radiography for inline treatment planning and positioning verification of small animals. Acta Oncol ³ gica, 2017, 56, 1399-1405.	0.8	11
110	Therapeutic options to overcome tumor hypoxia in radiation oncology. Clinical and Translational Imaging, 2017, 5, 455-464.	1.1	6
111	Modeling <i>in vivo</i> relative biological effectiveness in particle therapy for clinically relevant endpoints. Acta Oncol ³ gica, 2017, 56, 1392-1398.	0.8	18
112	Tumor heterogeneity determined with a ³ H2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. Radiotherapy and Oncology, 2017, 124, 379-385.	0.3	11
113	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	0.9	16
114	Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiotherapy and Oncology, 2017, 124, 185-189.	0.3	33
115	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. Radiotherapy and Oncology, 2017, 124, 496-503.	0.3	21
116	Development of a genetic sensor that eliminates p53 deficient cells. Nature Communications, 2017, 8, 1463.	5.8	15
117	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. Zeitschrift Fur Medizinische Physik, 2017, 27, 285-299.	0.6	5
118	Session 39: Modelling and simulation III. Biomedizinische Technik, 2017, 62, .	0.9	0
119	An optimized small animal tumour model for experimentation with low energy protons. PLoS ONE, 2017, 12, e0177428.	1.1	9
120	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	0.8	89
121	Precise image-guided irradiation of small animals: a flexible non-profit platform. Physics in Medicine and Biology, 2016, 61, 3084-3108.	1.6	39
122	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
123	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. Clinical and Translational Radiation Oncology, 2016, 1, 19-26.	0.9	22
124	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. Radiotherapy and Oncology, 2016, 121, 447-452.	0.3	8
125	Internal and external validation of an ESTRO delineation guideline – dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer. Radiotherapy and Oncology, 2016, 121, 424-430.	0.3	40
126	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0

#	ARTICLE	IF	CITATIONS
127	PRONTOX " proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 543.	0.7	20
128	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , 2016, 198, 107-122.	1.8	12
129	ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. <i>Radiotherapy and Oncology</i> , 2016, 118, 205-208.	0.3	162
130	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	3.2	127
131	Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1397-1403.	3.9	12
132	Radiation oncology in the era of precision medicine. <i>Nature Reviews Cancer</i> , 2016, 16, 234-249.	12.8	636
133	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2637-2651.	0.4	62
134	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184
135	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 350-358.	0.3	62
136	Early and late effects of radiochemotherapy on cerebral blood flow in glioblastoma patients measured with non-invasive perfusion MRI. <i>Radiotherapy and Oncology</i> , 2016, 118, 24-28.	0.3	32
137	Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment " Does that matter?. <i>Radiotherapy and Oncology</i> , 2016, 118, 211-213.	0.3	3
138	Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. <i>Radiation Oncology</i> , 2015, 10, 172.	1.2	36
139	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 256.	1.3	18
140	DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. <i>Seminars in Radiation Oncology</i> , 2015, 25, 237-250.	1.0	59
141	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1165-1174.	0.4	89
142	Simultaneous β 21 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	78
143	Aldehyde Dehydrogenase Is Regulated by β 2-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. <i>Cancer Research</i> , 2015, 75, 1482-1494.	0.4	195
144	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. <i>Radiation and Environmental Biophysics</i> , 2015, 54, 155-166.	0.6	27

#	ARTICLE	IF	CITATIONS
145	ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 3-10.	0.3	462
146	Corrigendum to "HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)" [Radiother. Oncol. 113 (2014) 317-323]. <i>Radiotherapy and Oncology</i> , 2015, 114, 419.	0.3	0
147	Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 124, 197-205.	1.4	15
148	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. <i>Radiotherapy and Oncology</i> , 2015, 115, 120-127.	0.3	47
149	γ H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. <i>Radiotherapy and Oncology</i> , 2015, 116, 473-479.	0.3	38
150	Implementation of a software for REmote COMparison of PARTicle and photon treatment plans: ReCompare. <i>Zeitschrift Fur Medizinische Physik</i> , 2015, 25, 287-294.	0.6	9
151	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. <i>Acta Oncologica</i> , 2015, 54, 1355-1363.	0.8	57
152	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. <i>Radiotherapy and Oncology</i> , 2015, 116, 486-494.	0.3	48
153	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. <i>Acta Oncologica</i> , 2015, 54, 1658-1664.	0.8	36
154	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. <i>Radiotherapy and Oncology</i> , 2014, 113, 303-309.	0.3	79
155	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. <i>Cancer Research</i> , 2014, 74, 2825-2834.	0.4	61
156	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.3	141
157	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. <i>Pharmaceuticals</i> , 2014, 7, 311-338.	1.7	62
158	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. <i>Radiation Oncology</i> , 2014, 9, 261.	1.2	9
159	Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 263-269.	1.0	15
160	Concept for individualized patient allocation: ReCompare "remote comparison of particle and photon treatment plans. <i>Radiation Oncology</i> , 2014, 9, 59.	1.2	16
161	Pre-clinical research in small animals using radiotherapy technology "a bidirectional translational approach. <i>Zeitschrift Fur Medizinische Physik</i> , 2014, 24, 335-351.	0.6	54
162	Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particles. <i>Radiation Oncology</i> , 2014, 9, 57.	1.2	18

#	ARTICLE	IF	CITATIONS
163	Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. <i>Radiotherapy and Oncology</i> , 2014, 111, 81-87.	0.3	34
164	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. <i>Radiotherapy and Oncology</i> , 2014, 110, 362-369.	0.3	49
165	Epidermal growth factor receptor targeting and its role for individualisation in radiation oncology. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 274.	2.2	0
166	GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , 2013, 106, 299-304.	0.3	49
167	Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2013, 108, 422-428.	0.3	14
168	Residual γ H2AX foci predict local tumour control after radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 108, 434-439.	0.3	37
169	Cetuximab Attenuates Its Cytotoxic and Radiosensitizing Potential by Inducing Fibronectin Biosynthesis. <i>Cancer Research</i> , 2013, 73, 5869-5879.	0.4	53
170	Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 1125-1132.	1.0	1
171	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. <i>Radiotherapy and Oncology</i> , 2012, 102, 444-449.	0.3	26
172	Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. <i>BMC Cancer</i> , 2012, 12, 217.	1.1	19
173	Individualization of cancer treatment from radiotherapy perspective. <i>Molecular Oncology</i> , 2012, 6, 211-221.	2.1	68
174	β 1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. <i>Journal of Clinical Investigation</i> , 2012, 122, 1529-1540.	3.9	194
175	3D Semi-quantification of Nanoparticle Content in Tissue on Experimental and Commercial μ CT-Scanner. <i>Springer Proceedings in Physics</i> , 2012, , 111-115.	0.1	0
176	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. <i>Radiotherapy and Oncology</i> , 2011, 99, 323-330.	0.3	78
177	Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. <i>Radiotherapy and Oncology</i> , 2011, 100, 137-144.	0.3	40
178	Radiotherapy and "new" drugs-new side effects?. <i>Radiation Oncology</i> , 2011, 6, 177.	1.2	53
179	Cellular and Tumor Radiosensitivity is Correlated to Epidermal Growth Factor Receptor Protein Expression Level in Tumors Without EGFR Amplification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1181-1188.	0.4	38
180	EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks. <i>Cancer Research</i> , 2011, 71, 6261-6269.	0.4	105

#	ARTICLE	IF	CITATIONS
181	Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 7224-7229.	3.2	106
182	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1019-1028.	1.2	26
183	Cancer stem cells at the crossroads of current cancer therapy failures—Radiation oncology perspective. <i>Seminars in Cancer Biology</i> , 2010, 20, 116-124.	4.3	97
184	CD44: A Cancer Stem Cell-Related Biomarker with Predictive Potential for Radiotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 5091-5093.	3.2	93
185	Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification. <i>Cancer Research</i> , 2010, 70, 3925-3934.	0.4	165
186	Effect of cetuximab and fractionated irradiation on tumour micro-environment. <i>Radiotherapy and Oncology</i> , 2010, 97, 322-329.	0.3	28
187	Cancer stem cells and radiotherapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 391-402.	1.0	75
188	Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by γ H2AX staining. <i>International Journal of Radiation Biology</i> , 2009, 85, 1032-1041.	1.0	70
189	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. <i>International Journal of Radiation Biology</i> , 2009, 85, 943-954.	1.0	38
190	The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. <i>Radiotherapy and Oncology</i> , 2009, 90, 257-264.	0.3	48
191	Tumor Biology's Impact on Clinical Cure Rates. <i>Medical Radiology</i> , 2009, , 323-334.	0.0	6
192	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 387-402.	2.7	26
193	Effects of Lovastatin Alone or Combined with Irradiation on Tumor Cells in Vitro and in Vivo. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 48-53.	1.0	27
194	Clonogens and cancer stem cells. <i>Nature Reviews Cancer</i> , 2008, 8, 990-990.	12.8	9
195	Exploring the role of cancer stem cells in radioresistance. <i>Nature Reviews Cancer</i> , 2008, 8, 545-554.	12.8	766
196	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. <i>Radiotherapy and Oncology</i> , 2008, 88, 258-268.	0.3	130
197	Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation. <i>International Journal of Radiation Biology</i> , 2007, 83, 827-836.	1.0	7
198	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. <i>Radiotherapy and Oncology</i> , 2007, 82, 96-104.	0.3	43

#	ARTICLE	IF	CITATIONS
199	EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. <i>Radiotherapy and Oncology</i> , 2007, 83, 238-248.	0.3	170
200	EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumorigenic cells?. <i>Radiotherapy and Oncology</i> , 2007, 83, 316-325.	0.3	51
201	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2007, 83, 304-310.	0.3	144
202	Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 256-264.	1.0	64
203	Experimental Evaluation of Functional Imaging for Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 41-42.	1.0	6
204	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. <i>Radiotherapy and Oncology</i> , 2006, 80, 112-122.	0.3	78
205	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. <i>Radiotherapy and Oncology</i> , 2006, 81, 122-129.	0.3	102
206	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 908-914.	0.4	46
207	Ultrafractionation does not Improve the Results of Radiotherapy in Radioresistant Murine DDL1 Lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 540-544.	1.0	17
208	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. <i>Radiotherapy and Oncology</i> , 2005, 74, 331-336.	0.3	20
209	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. <i>Radiotherapy and Oncology</i> , 2005, 76, 206-212.	0.3	40
210	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2005, 76, 162-167.	0.3	85
211	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. <i>Radiotherapy and Oncology</i> , 2005, 76, 151-156.	0.3	27
212	Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. <i>International Journal of Radiation Biology</i> , 2005, 81, 751-758.	1.0	35
213	TCP and NTCP in preclinical and clinical research in Europe. <i>Rays</i> , 2005, 30, 121-6.	0.2	7
214	Effect of the Hypoxic Cell Sensitizer Isometronidazole on Local Control of Two Human Squamous Cell Carcinomas after Fractionated Irradiation. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 375-382.	1.0	17
215	Molecular targeting in radiotherapy of lung cancer. <i>Lung Cancer</i> , 2004, 45, S187-S197.	0.9	23
216	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. <i>Radiotherapy and Oncology</i> , 2004, 72, 257-266.	0.3	161

#	ARTICLE	IF	CITATIONS
217	Ultrafractionation in human malignant glioma xenografts. <i>International Journal of Cancer</i> , 2003, 107, 333-333.	2.3	11
218	In regard to Solomon et al.: EGFR blockade with ZD1839 (â€œressaâ€) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. <i>IJROBP</i> 2003;55:713â€“723. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 300-301.	0.4	5
219	Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. <i>Anticancer Research</i> , 2003, 23, 3869-76.	0.5	43
220	Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 483-493.	0.4	101